249 related articles for article (PubMed ID: 19470922)
21. Inhibition of intestinal tumorigenesis in Apc(min/+) mice by green tea polyphenols (polyphenon E) and individual catechins.
Hao X; Sun Y; Yang CS; Bose M; Lambert JD; Ju J; Lu G; Lee MJ; Park S; Husain A; Wang S
Nutr Cancer; 2007; 59(1):62-9. PubMed ID: 17927503
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy.
Zhao H; Zhu W; Jia L; Sun X; Chen G; Zhao X; Li X; Meng X; Kong L; Xing L; Yu J
Br J Radiol; 2016; 89(1058):20150665. PubMed ID: 26607642
[TBL] [Abstract][Full Text] [Related]
24. Human salivary tea catechin levels and catechin esterase activities: implication in human cancer prevention studies.
Yang CS; Lee MJ; Chen L
Cancer Epidemiol Biomarkers Prev; 1999 Jan; 8(1):83-9. PubMed ID: 9950244
[TBL] [Abstract][Full Text] [Related]
25. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin.
Pangalis GA; Siakantaris MP; Angelopoulou MK; Vassilakopoulos TP; Dimopoulou MN; Kyrtsonis MC; Konstantopoulos K; Tsaftaridis P; Vaiopoulos GA; Kontopidou FN
Haematologica; 2002 May; 87(5):500-6. PubMed ID: 12010663
[TBL] [Abstract][Full Text] [Related]
26. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
27. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
[TBL] [Abstract][Full Text] [Related]
28. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.
Shanafelt TD; Kay NE; Rabe KG; Call TG; Zent CS; Maddocks K; Jenkins G; Jelinek DF; Morice WG; Boysen J; Schwager S; Bowen D; Slager SL; Hanson CA
J Clin Oncol; 2009 Aug; 27(24):3959-63. PubMed ID: 19620484
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.
Jensen M; Engert A; Weissinger F; Knauf W; Kimby E; Poynton C; Oliff IA; Rummel MJ; Osterborg A
Invest New Drugs; 2008 Apr; 26(2):139-49. PubMed ID: 18094935
[TBL] [Abstract][Full Text] [Related]
31. Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial.
Zhu W; Mei H; Jia L; Zhao H; Li X; Meng X; Zhao X; Xing L; Yu J
Invest New Drugs; 2020 Aug; 38(4):1129-1136. PubMed ID: 31701429
[TBL] [Abstract][Full Text] [Related]
32. Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia.
D'Arena G; Simeon V; De Martino L; Statuto T; D'Auria F; Volpe S; Deaglio S; Maidecchi A; Mattoli L; Mercati V; Musto P; De Feo V
Int J Immunopathol Pharmacol; 2013; 26(1):117-25. PubMed ID: 23527714
[TBL] [Abstract][Full Text] [Related]
33. Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Byrd JC; Woyach JA; Furman RR; Martin P; O'Brien S; Brown JR; Stephens DM; Barrientos JC; Devereux S; Hillmen P; Pagel JM; Hamdy A; Izumi R; Patel P; Wang MH; Jain N; Wierda WG
Blood; 2021 Jun; 137(24):3327-3338. PubMed ID: 33786588
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
35. Chemiluminescence-high-performance liquid chromatographic determination of tea catechin, (-)-epigallocatechin 3-gallate, at picomole levels in rat and human plasma.
Nakagawa K; Miyazawa T
Anal Biochem; 1997 May; 248(1):41-9. PubMed ID: 9177723
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
37. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M
Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
39. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
40. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions.
Ahn WS; Yoo J; Huh SW; Kim CK; Lee JM; Namkoong SE; Bae SM; Lee IP
Eur J Cancer Prev; 2003 Oct; 12(5):383-90. PubMed ID: 14512803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
